Off-target activity of TNF-α inhibitors characterized by protein biochips

Analytical and Bioanalytical Chemistry

Volumn 391, Issue 5, 2008, Pages 1713-1720

  Feyen, Oliver ^a   Lueking, Angelika ^b   Kowald, Axel ^c   Stephan, Christian ^c   Meyer, Helmut E ^c   Göbel, Ulrich ^a   Niehues, Tim ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b PROTAGEN AG   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Adalimumab; Etanercept; Infliximab; Off target activity; Protein biochip; Specificity analysis

Indexed keywords

BIOASSAY; BIOCHIPS; BIOMOLECULES; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; DRUG INTERACTIONS; DRUG THERAPY; GLYCOPROTEINS; HEALTH; MACROPHAGES; MICROARRAYS; PATIENT TREATMENT; PROTEINS; TARGETS; TISSUE; TUMORS;

BIO-ANALYSIS; BIOLOGICAL DRUGS; FUSION PROTEINS; HUMAN PROTEINS; IN-VITRO; PROTEIN BIOCHIPS; PROTEIN SEQUENCING; RECEPTOR (IR); RIBOSOMAL PROTEIN (R PROTEIN); RIBOSOME BIOGENESIS; SEQUENCE HOMOLOGY; SIDE EFFECTS; SPRINGER (CO); TARGET ACTIVITY; TUMOR NECROSIS FACTOR (NCF);

ANTIBODIES;

ADALIMUMAB; ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; RIBOSOME PROTEIN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; JUVENILE RHEUMATOID ARTHRITIS; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY; PROTEIN MICROARRAY; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; BINDING SITES; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; PROTEIN ARRAY ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RIBOSOMAL PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45849107231     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-008-1938-7     Document Type: Article

References (37)

1. Walter G, Büssow K, Cahill D, Lueking A, Lehrach H (2000) Protein arrays for gene expression and molecular interaction screening. Curr Opin Microbiol 3:298-302
2. Cahill DJ (2001) Protein and antibody arrays and their medical applications. J Immunol Methods 250:81-91
3. Lueking A, Possling A, Huber O, Beveridge A, Horn M, Eickhoff H, Schuchardt J, Lehrach H, Cahill DJ (2003) A nonredundant human protein chip for antibody screening and serum profiling. Mol Cell Proteomics 2:1342-1349
4. Michaud GA, Salcius M, Zhou F, Bangham R, Bonin J, Guo H, Snyder M, Predki PF, Schweitzer BI (2003) Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol 21:1509-1512
5. Ballow M (2005) -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science? J Allergy Clin Immunol 116:738-743
6. Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704-712
7. Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013-3022
8. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF (2003) Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29:2327-2329
9. Haerter G, Manfras BJ, de Jong-Hesse Y, Wilts H, Mertens T, Kern P, Schmitt M (2004) Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 39:e88-e94
10. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148-155
11. Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34(Suppl):34-38
12. Wallis RS, Broder M, Wong J, Lee A, Hoq L (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41(Suppl):S194-S198
13. Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41(Suppl):S199-S203
14. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, Attract Study Group (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939
15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594-1602
16. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259
17. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478-486
18. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, Taborn J, Weaver A, Burge DJ, Schiff MH (2001) Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 28:1238-1244
19. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563-2571
20. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508-516
21. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, Crohn's disease cA2 study group (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337:1029-1035
22. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385-390
23. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591
24. Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42:617-621
25. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M (2007) Infections during tumour necrosis factor-{alpha} inhibitor therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46:327-334
26. Lueking A, Huber O, Wirths C, Schulte K, Stieler KM, Blume-Peytavi U, Kowald A, Hensel-Wiegel K, Tauber R, Lehrach H, Meyer HE, Cahill DJ (2005) Profiling of alopecia areata auto-antigens based on protein microarray technology. Mol Cell Proteomics 4:1382-1390
27. Nicodeme P (2001) Fast approximate motif statistics. J Comput Biol 8(3):235-248
28. Gershoni JM (1988) Protein blotting: a manual. Methods Biochem Anal 33:1-58
29. Zeng F-Y, Oka JA, Weigel PH (1996) Renaturation and ligand blotting of the major subunit of the rat asialoglycoprotein receptor after denaturing polyacrylamide gel electrophoresis. Glycobiology 6:247-255
30. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
31. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295-299
32. Keystone EC (2005) Safety of biologic therapies-an update. J Rheumatol 74(Suppl):8-12
33. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261-1265
34. Nestea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ (2003) Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 48:1853-1857
35. Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013-3022
36. Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-(alpha) antagonists. Medicine 84:291-302
37. Sakanyan V (2005) High-throughput and multiplexed protein array technology: protein-DNA and protein-protein interactions. J Chromatogr B 815:77-95